← Back to Search

Alpha-1 Adrenergic Receptor Antagonist

Nyxol Eye Drops + Low-Dose Pilocarpine Eye Drops for Presbyopia (VEGA-2 Trial)

Phase 3
Waitlist Available
Research Sponsored by Ocuphire Pharma, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at 30 min post-ldp/vehicle comparing nyxol + ldp to nyxol alone at visit 5 (stage 2 day 8)
Awards & highlights

VEGA-2 Trial Summary

This trial will test a new eye treatment to improve near vision in people with presbyopia.

VEGA-2 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at 30 min post-ldp/vehicle comparing nyxol + ldp to nyxol alone at visit 5 (stage 2 day 8)
This trial's timeline: 3 weeks for screening, Varies for treatment, and at 30 min post-ldp/vehicle comparing nyxol + ldp to nyxol alone at visit 5 (stage 2 day 8) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percent of subjects with ≥ 15 letters of improvement in photopic binocular DCNVA and with < 5 letters of loss in photopic binocular BCDVA in Nyxol-treated subjects
Secondary outcome measures
Change and percent change in mesopic PD from Baseline
Change and percent change in photopic PD from Baseline
Change in mesopic binocular DCNVA from Baseline
+14 more

VEGA-2 Trial Design

4Treatment groups
Experimental Treatment
Group I: Placebo + low dose pilocarpine vehicleExperimental Treatment2 Interventions
Group II: Placebo + low dose pilocarpineExperimental Treatment2 Interventions
Group III: Nyxol + low dose pilocarpine vehicleExperimental Treatment2 Interventions
Group IV: Nyxol + low dose pilocarpineExperimental Treatment2 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Phentolamine Opthalmic Solution 0.75%
2022
Completed Phase 3
~340
Low dose pilocarpine
2022
Completed Phase 3
~340

Find a Location

Who is running the clinical trial?

Ocuphire Pharma, Inc.Lead Sponsor
10 Previous Clinical Trials
1,128 Total Patients Enrolled
1 Trials studying Presbyopia
150 Patients Enrolled for Presbyopia

Media Library

Phentolamine Ophthalmic Solution 0.75% (Alpha-1 Adrenergic Receptor Antagonist) Clinical Trial Eligibility Overview. Trial Name: NCT05646719 — Phase 3
Presbyopia Research Study Groups: Nyxol + low dose pilocarpine, Nyxol + low dose pilocarpine vehicle, Placebo + low dose pilocarpine, Placebo + low dose pilocarpine vehicle
Presbyopia Clinical Trial 2023: Phentolamine Ophthalmic Solution 0.75% Highlights & Side Effects. Trial Name: NCT05646719 — Phase 3
Phentolamine Ophthalmic Solution 0.75% (Alpha-1 Adrenergic Receptor Antagonist) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05646719 — Phase 3
Presbyopia Patient Testimony for trial: Trial Name: NCT05646719 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Can you elucidate the dangers of administering Nyxol and low dose pilocarpine to patients?

"With prior clinical data attesting to its safety, Nyxol + low dose pilocarpine was evaluated and assigned a score of 3."

Answered by AI

Are any vacancies still available for enrollment in this research?

"Clinicaltrials.gov reports that the recruitment process for this medical study is still ongoing; it was initially posted on December 22nd 2022 with its most recent edit taking place on February 24th 2023."

Answered by AI

Does this research program accept elderly participants?

"This medical trial has a 40-year old minimum age limit and an upper threshold of 64 years."

Answered by AI

How many participants are eligible to join this clinical research program?

"Ocuphire Pharma, Inc. will be conducting the trial at two sites: Phoenix in Arizona and Azusa in California. In order to successfully complete this study, 320 patients meeting all inclusion criteria must participate."

Answered by AI

Who else is applying?

What state do they live in?
Arizona
What site did they apply to?
Northridge, CA
Austin, TX
Other
Phoenix, AZ
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
How many prior treatments have patients received?
0
1

Why did patients apply to this trial?

Tired of having to 'get my readers' every time I need to look at ingredients, a recipe, or a medication.
PatientReceived no prior treatments
~148 spots leftby Mar 2025